Highlights the clinical challenge of managing patients with atrial fibrillation undergoing PCI, who require both anticoagulation for stroke prevention and antiplatelet therapy for stent thrombosis prevention.
The management of atrial fibrillation in patients who have undergone percutaneous coronary intervention (PCI) for the treatment of coronary-artery disease is a common and difficult challenge. In patients with atrial fibrillation, oral anticoagulation is administered to reduce the risk of stroke. In patients who have undergone PCI, dual antiplatelet therapy is administered to prevent major adverse cardiovascular events and stent thrombosis. The use of triple therapy is common in clinical practice; one in four older patients with atrial fibrillation who have had an acute myocardial infarction receives triple therapy.1 Although triple therapy may minimize the risk of stent thrombosis and . . .
No takes yet. Share an insight, caveat, or question.
Piccini et al. (2017) conducted an editorial in Atrial fibrillation after PCI. Triple therapy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: